AI
By
Can Absci’s AI-Powered Drug Platform Disrupt $600M+ Biopharma Pipelines by 2026?
Absci blends AI and biology—end-to-endUnlike other AI drug startups that rely on outsourcing, Absci integrates generative AI with…
Can Chugai (Roche subsidiary) and Gero’s $250M AI-Driven Alliance Unlock a New Era in Anti-Aging Therapies?
Key Takeaways: AI-Powered Target Discovery Meets World-Class Antibody EngineeringThe joint research and license agreement between Tokyo-based Chugai Pharmaceutical…
Could AbbVie and IGI’s $1.9B Bet on AI-Engineered Trispecific Antibody Signal a New Era for Relapsed Myeloma Treatment?
Key Highlights: AbbVie Accelerates into AI-Powered Immuno-OncologyAbbVie has entered a global licensing agreement worth up to $1.925 billion…
Can Personalis and Tempus Leverage AI to Transform Cancer Recurrence Detection for 150,000 Colorectal Patients? Strategic Expansion Deepens MRD Leadership
Key Highlights AI at the Core of Next-Gen Recurrence MonitoringThe expansion of Personalis’ NeXT Personal® MRD test into…
Will Sanofi’s AI Ethics Revolution Trigger a $100 Billion Shift in Biopharma and Medtech? How the Company’s Transparency Drive is Reshaping Global Healthcare
Key Highlights: AI Ethics at Scale: Sanofi Sets Global Leadership StandardSanofi’s establishment of a dedicated AI Ethical Review…
Is Thermo Fisher’s $10B Q2 Surge the Inflection Point for AI-Powered Biopharma? How Will It Reshape the Life Sciences Landscape?
Key Highlights Financial Resilience and Strategic MarginsThermo Fisher Scientific’s Q2 2025 report showcases its fortress-like financial discipline. With…
